Shin Nippon Biomedical Laboratories, Ltd. (TSE: 2395)
Health Care · Life Sciences Tools & Services · JP
¥1,443.00
+11.60% today · -11.6% 1Y
Shin Nippon Biomedical Laboratories, Ltd. (TSE: 2395) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $379.40M and employs 1,680 people.
Over the last twelve months the share price has lost 11.6%, trading between 1.07K and 2.00K.
Tweenvest scores Shin Nippon Biomedical Laboratories, Ltd. across four factors: quality 61/100, value 77/100, growth 41/100, dividend 90/100. Its strongest factor is dividend.
2395 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $379.40M
- Revenue (TTM)
- $208.66M
- P/E
- 11.19
- EPS
- 129.00
- Dividend yield
- 3.46%
- Beta (5Y)
- -0.16
- 52-week high
- ¥2,005.00
- 52-week low
- ¥1,067.00
- Avg volume (3M)
- —
- Shares outstanding
- 41.63M
- Employees
- 1,680
- Next earnings
- —
About Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array of laboratory services, including regulatory-compliant good laboratory practice (GLP) inspections. These studies cover general and specialized toxicity assessments, detailed pathological examinations, pharmacokinetic (PK) and pharmacodynamic (PD) analysis for biopharmaceuticals, immunotoxicity testing, and antibody production. The company also conducts investigations into reproductive and developmental toxicity, pharmacological mechanisms, and efficacy, alongside providing various imaging services. Furthermore, the organization specializes in developing and validating analytical methodologies, analyzing biological specimens, and determining pharmacokinetic parameters. It also conducts studies on absorption, distribution, metabolism, and excretion (ADME), often utilizing radioisotope-labeled compounds. Beyond preclinical and analytical work, it extends its expertise to clinical trial support through site management organization (SMO) services and broader clinical contract research organization (CRO) support. Its translational research division focuses on advancing novel medical solutions, such as the development of nasal drug delivery systems, nucleic acid-based adjuvants, and regenerative medicine therapies. Established in 1957, Shin Nippon Biomedical Laboratories, Ltd. maintains its headquarters in Tokyo, Japan.
- ISIN
- JP3379950003
- Founded
- 1957
- Listed since
- Mar 8, 2004
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| SMO ClinPlus CO.,LTD.SZSE: 301257 | $475.34M | CN¥40.30 | -5.64% |
| Alpha Teknova, Inc.NasdaqGM: TKNO | $474.60M | $8.84 | -1.67% |
| Viva Biotech HoldingsSEHK: 1873 | $408.85M | HK$1.55 | +1.31% |
| Zhejiang Tailin BioEngineering Co.,LtdSZSE: 300813 | $403.22M | CN¥22.51 | -1.40% |
| Medtide Inc.SEHK: 3880 | $375.12M | HK$20.76 | -1.98% |
| Quantum-Si incorporatedNasdaqGM: QSI | $334.89M | $1.53 | +25.41% |
| Zhejiang Taimei Medical Technology Co., Ltd.SEHK: 2576 | $320.71M | HK$4.50 | -5.26% |
| Improve Medical Instruments Co., Ltd.SZSE: 300030 | $318.97M | CN¥6.91 | -0.14% |
Figures last refreshed Oct 11, 2026.